Allogene Therapeutics, Inc.
ALLOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAllogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. At a $680.6M market cap, Allogene Therapeutics, Inc. ranks as a small-cap company within healthcare. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
Market Cap
$680.6M
Beta
0.48
P/E (TTM)
—
P/E (Fwd)
-3.02
EPS (TTM)
$-0.66
EPS (Fwd)
$-0.65
ROE
-42.4%
ROA
-22.1%
Cash
$332.6M
Total Debt
$79.0M
Free CF
-$63.5M
52W Change
72.8%
Annual Financials
Cash vs Debt
Where ALLO stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ALLO finished 6.13% below its 150-day moving average ($2.12) and 1.53% above its 200-day moving average ($1.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALLO overbought or oversold?
At the September 2, 2026 close, ALLO's RSI(14) was 46.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $332.6M in cash and $79.0M in debt, ALLO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$63.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -42.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $156K (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.48 suggests ALLO is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, ALLO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Allogene Therapeutics, Inc. and its sector.